心血管疾病相关血糖管理是临床研究的重要课题. SGLT2-I系列研究证实,优选的降糖药物治疗能够给患者带来心血管获益. UKPDS试验后10年随访研究显示,优化的降糖方案能够带来长期的后续保护效应.针对个体患者,指南推荐综合管理、个体化治疗,关注低血糖的不良效应.
Management of blood glucose in cardiovascular disease is an important topic in clinical research. In recent years, series of SGLT2-I studies reveal that optimal drug could result in cardiovascular benefits to patients. 10-year follow-up of UKPDS trial confirm that an optimized hypoglycemic regimen could lead to long-term protective effects. As for individuals, guidelines recommend that integrated management, individualized treatment, and attention to the adverse effects of hypoglycemia.